Denali Therapeutics (Nasdaq: DNLI) will report its second quarter 2026 financial results and business highlights for the period ended June 30, 2026, on Thursday, August 6, 2026. Management will host a conference call and webcast at 4:30 p.m. ET (1:30 p.m. PT) to discuss the results and provide a business update.
The live webcast and slide presentation will be available via the Investors section of Denali’s website, with a replay archived for a limited time. Denali describes itself as a biotechnology company developing biotherapeutics that cross the blood-brain barrier using its TransportVehicle™ platform.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – DNLI
+2.04%
5 alerts
+2.04%Session close to close
+3.4%Peak Tracked
-3.9%Trough Tracked
$3.89BMarket Cap
0.7xRel. Volume
In the Jul 28 session, DNLI gained 2.04%, reflecting a moderate positive market reaction.
Argus tracked a peak move of +3.4% during that session.
Argus tracked a trough of -3.9% from its starting point during tracking.
Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
The prior earnings event was followed by a -0.46% 24-hour move, while DNLI's recent news record incl...
Analysis
The prior earnings event was followed by a -0.46% 24-hour move, while DNLI's recent news record included four negative reactions among five events. The scheduled update leaves results and business metrics unreported; watch the disclosed figures and outlook.
"designed to cross the blood-brain barrier (BBB) using its proprietary"
A protective barrier of tightly packed cells and supporting tissue that controls what substances in the blood can enter the brain, acting like a security checkpoint that keeps out most pathogens and many drugs while allowing essential nutrients through. For investors, the barrier matters because whether a therapy can cross or safely bypass it often determines clinical success, regulatory approval and commercial potential for treatments of brain disorders.
FDA-approvedregulatory
"the first FDA-approved biologic specifically designed to cross the BBB"
FDA-approved means a medical product, drug, device or treatment has passed the U.S. Food and Drug Administration’s review for safety and effectiveness for a specific use. Think of it like a formal safety and performance seal that allows the product to be marketed for that purpose in the U.S.; for investors, approval reduces regulatory uncertainty, enables sales and reimbursement pathways, and can materially affect a company’s revenue prospects and valuation.
lysosomal storage disordersmedical
"neurodegenerative diseases, lysosomal storage disorders and other serious diseases"
A group of inherited conditions where cells cannot break down and clear certain molecules, like a clogged recycling center inside cells causing harmful buildup that damages organs and the nervous system. Investors care because these disorders create clear targets for specialized treatments, often qualify for orphan-drug incentives and accelerated review, and can drive focused clinical programs and high-value niche markets if therapies prove safe and effective.
SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it will report financial results and business highlights for the second quarter ended June 30, 2026, on Thursday, August 6, 2026.
Following the announcement, Denali's management will host a conference call and webcast on Thursday, August 6, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss Denali’s second quarter 2026 financial results and provide a general business update.
The live webcast, along with an accompanying slide presentation, may be accessed through the Investors section of Denali's website at www.denalitherapeutics.com or by clicking here. A replay of the webcast will be archived on Denali’s website for a limited time following the call.
About Denali Therapeutics
Denali Therapeutics Inc. is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier (BBB) using its proprietary TransportVehicle™ platform. With the first FDA-approved biologic specifically designed to cross the BBB, a clinically validated delivery platform and a growing portfolio of therapeutic candidates across all stages of development, Denali is advancing toward its goal of delivering effective medicines to transform life for people with neurodegenerative diseases, lysosomal storage disorders and other serious diseases. For more information, please visit www.denalitherapeutics.com.
Investor Contact:
Laura Hansen
hansen@dnli.com
FAQ
When will Denali Therapeutics (DNLI) report its Q2 2026 financial results?
Denali Therapeutics plans to report its Q2 2026 financial results on Thursday, August 6, 2026. According to Denali Therapeutics, the report will cover the quarter ended June 30, 2026, and will be accompanied by a management conference call and webcast.
What time is Denali Therapeutics (DNLI) Q2 2026 earnings conference call on August 6, 2026?
The Denali Therapeutics Q2 2026 earnings call is scheduled for 4:30 p.m. Eastern Time on August 6, 2026. According to Denali Therapeutics, this corresponds to 1:30 p.m. Pacific Time and will include financial results and a general business update.
How can investors access the Denali Therapeutics (DNLI) Q2 2026 earnings webcast?
Investors can access the Denali Therapeutics Q2 2026 earnings webcast through the Investors section of the company’s website. According to Denali Therapeutics, the live webcast will include slides, and a replay will be archived online for a limited period.
Will there be a replay of the Denali Therapeutics (DNLI) Q2 2026 earnings call?
Yes, a replay of the Denali Therapeutics Q2 2026 earnings webcast will be available on the company’s website. According to Denali Therapeutics, the archived replay will remain accessible in the Investors section for a limited time following the call.
What does Denali Therapeutics (DNLI) focus on in its biotechnology pipeline?
Denali Therapeutics focuses on biotherapeutics designed to cross the blood-brain barrier using its TransportVehicle platform. According to Denali Therapeutics, it has an FDA-approved biologic using this approach and a pipeline targeting neurodegenerative diseases, lysosomal storage disorders, and other serious conditions.
What will Denali Therapeutics discuss during the Q2 2026 DNLI earnings call?
Denali Therapeutics will discuss second quarter 2026 financial results and provide a general business update. According to Denali Therapeutics, management will review performance for the quarter ended June 30, 2026, and highlight key business developments during the webcast.
